United Kingdom

Time filter

Source Type

LONDON, ENGLAND / ACCESSWIRE / May 8, 2017 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a conference call and live webcast to discuss the results of the second quarter 2017, to be held Tuesday, May 9, 2017 at 4:30 PM Eastern Time. To participate, connect approximately 5 to 10 minutes before the beginning of the event. If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.gwpharm.com. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.


- Epidiolex® NDA submission expected mid-year - - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology - - Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter ended 31 March 2017.                                        “Our primary focus is on the submission of the Epidiolex NDA, which is expected in the middle of this year. Based on the efficacy and safety profile, we are confident in the prospects for an Epidiolex approval and continue to expand the commercial organization in preparation for a highly successful launch,” stated Justin Gover, GW’s Chief Executive Officer. “Beyond Epidiolex, we continue to advance a number of additional exciting clinical programs.” • Epidiolex (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS) Solely for the convenience of the reader, the above balances have been translated into U.S. dollars at the rate on 31 March 2017 of $1.25331 to £1. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date. Conference Call and Webcast Information GW Pharmaceuticals will host a conference call and webcast to discuss the second quarter 2017 financial results today at 4:30 pm EDT. To participate in the conference call, please dial 800-860-2442 (toll free from the U.S. and Canada) or 412-858-4600 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010, (international):1-919-882-2331. For both dial-in numbers please use conference ID # 13661781. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com. This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex and Epidiolex and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Condensed consolidated statement of comprehensive loss For the three months ended 31 March 2017 Condensed consolidated statement of comprehensive loss For the six months ended 31 March 2017 GW Pharmaceuticals plc Condensed consolidated statement of changes in equity Six months ended 31 March 2017


News Article | May 15, 2017
Site: globenewswire.com

– Dr. Volker Knappertz appointed Chief Medical Officer – – Professor Ben Whalley to join as Head of Discovery Research – LONDON, May 15, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced the appointment of Volker Knappertz, M.D. as Chief Medical Officer (CMO). Reporting to GW’s Chief Executive Officer Justin Gover, Dr. Knappertz will be based in the Company’s U.S. headquarters in Carlsbad, California. In addition, GW has appointed Prof. Ben Whalley as Head of Discovery Research, based in the UK. “I am delighted to welcome Volker and Ben to GW in these important R&D roles,” stated Justin Gover, GW’s Chief Executive Officer. “Volker has an impressive record of successful new drug development and obtaining regulatory approvals which, together with his deep experience in neurology, makes him ideally suited to lead GW’s clinical and regulatory activities with respect to Epidiolex® and our product pipeline. In addition, Ben’s prominent position in the field of cannabinoid science, particularly with respect to epilepsy, will also be a major asset to GW in the pursuit of our pipeline discovery programs.” Dr. Knappertz has over 25 years of clinical trial experience and 17 years of pharmaceutical drug development experience, holding leadership positions with responsibilities for managing international clinical trial and medical affairs programs. Most recently, as the Vice President of clinical development for multiple sclerosis, oncology and biosimilar products at Teva Pharmaceuticals, Dr. Knappertz oversaw multiple regulatory submissions and approvals in the U.S., Canada, Europe and Japan. Prior to joining Teva in 2012, Dr. Knappertz served in clinical and medical roles in CNS, CV, and biologics at Bayer Pharmaceuticals and AstraZeneca. Dr. Knappertz is a U.S. Board certified neurologist who received his residency training at Yale University, New Haven, CT where he served as chief resident and was fellowship trained at Wake Forest University, Winston-Salem, NC. He received his clinical scientist training and M.D. as well as a doctorate degree in research on glioblastoma from the University at Cologne in Germany. In addition to the appointment of Dr. Knappertz as CMO, Professor Ben Whalley has been appointed to the newly created position of Head of Discovery Research. Previously, Prof. Whalley was Professor of Neuropharmacology at the Reading School of Pharmacy at the University of Reading, UK Since 2007, he has been GW’s principal academic collaborator in the field of epilepsy pre-clinical research and is the author of key papers related to the pre-clinical studies of CBD and CBDV in the treatment of seizures. In this time, he has become a leading authority on the effects of cannabinoids in the central nervous system. “I am truly excited about the opportunity to continue the work of providing regulatory approved cannabinoid-based pharmaceutical medicines to patients with high unmet medical needs and look forward to building on the progress of the Epidiolex program in treatment resistant forms of epilepsy and to driving GW’s rich pipeline of products forward,” stated Dr. Knappertz. “The strength of the Epidiolex data is compelling and it is a privilege to begin my work at GW with the late-stage development and regulatory submissions of Epidiolex. Personally, having experienced first hand in my family the devastating effects of epilepsy, the opportunity to contribute directly to making a new treatment available for those affected by these often intractable epilepsy conditions allows me to return my focus to the therapeutic area that motivated my career as a neurologist and drug developer.” “Having now worked for the last decade in collaboration with GW to explore the pre-clinical effects of cannabinoids, I am convinced of the breadth of the potential of cannabinoid science to provide breakthroughs not only in epilepsy but across a range of disease areas,” stated Professor Whalley. “I look forward to contributing to GW’s drug discovery efforts and to advancing the next generation of pipeline candidates.” Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), an investigational product which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com. This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Epidiolex and the safety profile and commercial potential of Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY) as the Company announced on May 19, 2017, that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and adolescents aged 1 to 18 years with chronic phase Philadelphia chromosome positive chronic Myelogenous leukemia (CML). The agency also included the powder for oral suspension. Bristol-Myers Squibb stated that the validation of the application confirms the submission is complete and begins the EMA's centralized review process. Register with us now for your free membership and blog access at: One of Bristol-Myers Squibb's competitors within the Drug Manufacturers - Major space, GW Pharmaceuticals PLC (NASDAQ: GWPH), announced on May 09, 2017, its financial results for the second quarter ended 31 March 2017. AWS will be initiating a research report on GW Pharma in the coming days. Today, AWS is promoting its blog coverage on BMY; touching on GWPH. Get all of our free blog coverage and more by clicking on the link below: "Treatment options for pediatric patients with chronic phase CML, along with formulations that support the unique demands of children with cancer continue to be unmet needs," said Murdo Gordon, Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb, "Building on our long-standing heritage in hematology, including the use of Sprycel for more than a decade to treat adults with certain forms of CML, the validation of this application supports our commitment to expand options for children and adolescents with different types of cancer." Bristol-Myers Squibb's application included data from CA180-226 (NCT00777036), an ongoing Phase 2, open-label, non-randomized trial studying Sprycel in newly diagnosed chronic phase CML pediatric patients and in pediatric patients resistant to or intolerant of imatinib. The Company will be presenting data from this study at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on June 05, 2017. Bristol-Myers Squibb's Sprycel was first approved by the FDA in 2006 for the treatment of adults with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. At that time, Sprycel was also approved for adults with Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. Sprycel is approved and marketed worldwide for these indications in more than 60 countries. Sprycel is also an FDA-approved treatment for adults with newly diagnosed CP Ph+ CML, since October 2010. Sprycel received accelerated FDA approval for this indication. Additional country approvals for this indication total more than 50. SPRYCEL is approved for the treatment of newly diagnosed adults with Ph+ CML in chronic phase. Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and Ph+ ALL with resistance or intolerance to prior therapy. At the close of trading session on Friday, May 19, 2017, Bristol-Myers Squibb's stock price was marginally up by 0.45% to end the day at $54.02. A total volume of 8.63 million shares were exchanged during the session. The Company's share price has gained 1.09% in the past one month. The Company's shares are trading at a PE ratio of 18.73 and have a dividend yield of 2.89%. The stock currently has a market cap of $89.78 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | May 18, 2017
Site: www.marketwired.com

REDONDO BEACH, CA--(Marketwired - May 18, 2017) -  SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. ( : AXIM). SeeThruEquity recently initiated the stock with a $17 per share price target -- a 62% premium to the current market price of $10.52 per share, as of May 17, 2017. The article takes a closer look at the SeeThruEquity research report and the implications for AXIM moving forward. AXIM Biotech operates in the legal nutraceutical and pharmaceutical subset of the cannabis industry, but SeeThruEquity notes the rapidly advancing legalization movement is likely to have an impact on its valuation and market perception. This may be especially true with the upcoming launch of several new exchange-traded funds (ETFs) that aim to target the cannabis industry since they will likely hold an oversized position in AXIM Biotech given its market capitalization. AXIM Biotech has several upcoming catalysts that could favorably impact its valuation over the coming quarters. The company launched its CanChew®, a patented, controlled-release cannabis chewing gum for general wellbeing, in all 50 states and 40 countries. With more than 10 commercial-ready products in nutraceutical, cosmeceutical, and oral care markets, the company is already generating revenue without the need for regulatory approvals. In addition to these products, the company has more than 20 clinical products planned and is in the process of developing pharmaceutical candidates using chewing gum and other delivery methods -- including suppositories, transdermals, and transconjuctivals. These products are expected to begin reporting trial results this year. SeeThruEquity pointed out that lesser-known products in the pipeline could become new category leaders. For instance, the company's Oraximax™ is a cannabinoid product that management hopes will define a new category of oral care products thanks to its anti-inflammatory, anti-proliferative, and bactericidal properties. The company also offers lozenge and skin care products that could have similar potential. SeeThruEquity views the stock as an "intriguing speculative company" targeting the rapidly growing market for legal cannabis products with "what appears to be differentiated intellectual property and bold development plans" along with an intention to uplist the stock to a higher exchange. In terms of financial performance, the analyst expects AXIM to begin generating meaningful revenue next year before truly ramping up by 2019. The analyst projects revenue of $49 million, EBITDA of $6.7 million, and earnings per share of $0.01 during 2019E, which would translate to a relatively modest 11.5x revenue multiple. The company has the potential to dramatically expand these revenues at a high margin through licensing opportunities as well. AXIM Biotech has the self-issued goal of reaching an annual run rate of $1 billion by 2025, including $203 million from nutraceuticals and $200 million from pharmaceuticals. With 17 patents and 20 trademarks, the company is positioned to grow its portfolio through both internal product development and licensing opportunities with other industry leaders. It points to leaders like GW Pharmaceuticals plc as an example of such ambitions. Please follow the link to read the full article: http://analysis.secfilings.com/articles/173-axim-biotech-soars-after-analyst-issues-17-price-target Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors. Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.


— New Pipeline report on Rett Syndrome - Pipeline Review, H1 2017 report provide comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Browse the 28 Tables and 10 Figures, 16 Company Profiles, Spread across 119 Pages Report Available at http://www.reportsnreports.com/reports/992885-rett-syndrome-pipeline-review-h1-2017.html . Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs. Rett Syndrome - Companies Involved in Therapeutics Development - Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Apteeus, ArmaGen Inc, Edison Pharmaceuticals Inc, Eloxx Pharmaceuticals Ltd, GW Pharmaceuticals Plc, Horizon Pharma Plc, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Neuren Pharmaceuticals Ltd, Neurolixis Inc, Newron Pharmaceuticals SpA, OPKO Health Inc, Sage Therapeutics Inc, Ultragenyx Pharmaceutical Inc Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992885. Rett Syndrome (Central Nervous System) pipeline market guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Rett Syndrome - Pipeline Review, H1 2017, report provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992885-rett-syndrome-pipeline-review-h1-2017.html


LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY) as the Company announced on May 19, 2017, that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and adolescents aged 1 to 18 years with chronic phase Philadelphia chromosome positive chronic Myelogenous leukemia (CML). The agency also included the powder for oral suspension. Bristol-Myers Squibb stated that the validation of the application confirms the submission is complete and begins the EMA's centralized review process. Register with us now for your free membership and blog access at: One of Bristol-Myers Squibb's competitors within the Drug Manufacturers - Major space, GW Pharmaceuticals PLC (NASDAQ: GWPH), announced on May 09, 2017, its financial results for the second quarter ended 31 March 2017. AWS will be initiating a research report on GW Pharma in the coming days. Today, AWS is promoting its blog coverage on BMY; touching on GWPH. Get all of our free blog coverage and more by clicking on the link below: "Treatment options for pediatric patients with chronic phase CML, along with formulations that support the unique demands of children with cancer continue to be unmet needs," said Murdo Gordon, Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb, "Building on our long-standing heritage in hematology, including the use of Sprycel for more than a decade to treat adults with certain forms of CML, the validation of this application supports our commitment to expand options for children and adolescents with different types of cancer." Bristol-Myers Squibb's application included data from CA180-226 (NCT00777036), an ongoing Phase 2, open-label, non-randomized trial studying Sprycel in newly diagnosed chronic phase CML pediatric patients and in pediatric patients resistant to or intolerant of imatinib. The Company will be presenting data from this study at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on June 05, 2017. Bristol-Myers Squibb's Sprycel was first approved by the FDA in 2006 for the treatment of adults with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. At that time, Sprycel was also approved for adults with Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. Sprycel is approved and marketed worldwide for these indications in more than 60 countries. Sprycel is also an FDA-approved treatment for adults with newly diagnosed CP Ph+ CML, since October 2010. Sprycel received accelerated FDA approval for this indication. Additional country approvals for this indication total more than 50. SPRYCEL is approved for the treatment of newly diagnosed adults with Ph+ CML in chronic phase. Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and Ph+ ALL with resistance or intolerance to prior therapy. At the close of trading session on Friday, May 19, 2017, Bristol-Myers Squibb's stock price was marginally up by 0.45% to end the day at $54.02. A total volume of 8.63 million shares were exchanged during the session. The Company's share price has gained 1.09% in the past one month. The Company's shares are trading at a PE ratio of 18.73 and have a dividend yield of 2.89%. The stock currently has a market cap of $89.78 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY) as the Company announced on May 19, 2017, that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and adolescents aged 1 to 18 years with chronic phase Philadelphia chromosome positive chronic Myelogenous leukemia (CML). The agency also included the powder for oral suspension. Bristol-Myers Squibb stated that the validation of the application confirms the submission is complete and begins the EMA's centralized review process. Register with us now for your free membership and blog access at: One of Bristol-Myers Squibb's competitors within the Drug Manufacturers - Major space, GW Pharmaceuticals PLC (NASDAQ: GWPH), announced on May 09, 2017, its financial results for the second quarter ended 31 March 2017. AWS will be initiating a research report on GW Pharma in the coming days. Today, AWS is promoting its blog coverage on BMY; touching on GWPH. Get all of our free blog coverage and more by clicking on the link below: "Treatment options for pediatric patients with chronic phase CML, along with formulations that support the unique demands of children with cancer continue to be unmet needs," said Murdo Gordon, Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb, "Building on our long-standing heritage in hematology, including the use of Sprycel for more than a decade to treat adults with certain forms of CML, the validation of this application supports our commitment to expand options for children and adolescents with different types of cancer." Bristol-Myers Squibb's application included data from CA180-226 (NCT00777036), an ongoing Phase 2, open-label, non-randomized trial studying Sprycel in newly diagnosed chronic phase CML pediatric patients and in pediatric patients resistant to or intolerant of imatinib. The Company will be presenting data from this study at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on June 05, 2017. Bristol-Myers Squibb's Sprycel was first approved by the FDA in 2006 for the treatment of adults with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. At that time, Sprycel was also approved for adults with Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. Sprycel is approved and marketed worldwide for these indications in more than 60 countries. Sprycel is also an FDA-approved treatment for adults with newly diagnosed CP Ph+ CML, since October 2010. Sprycel received accelerated FDA approval for this indication. Additional country approvals for this indication total more than 50. SPRYCEL is approved for the treatment of newly diagnosed adults with Ph+ CML in chronic phase. Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and Ph+ ALL with resistance or intolerance to prior therapy. At the close of trading session on Friday, May 19, 2017, Bristol-Myers Squibb's stock price was marginally up by 0.45% to end the day at $54.02. A total volume of 8.63 million shares were exchanged during the session. The Company's share price has gained 1.09% in the past one month. The Company's shares are trading at a PE ratio of 18.73 and have a dividend yield of 2.89%. The stock currently has a market cap of $89.78 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Russo E.B.,GW Pharmaceuticals
British Journal of Pharmacology | Year: 2011

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL -1. They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. © 2011 The British Pharmacological Society.


The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimers disease.


The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

Loading GW Pharmaceuticals collaborators
Loading GW Pharmaceuticals collaborators